Two FLAMINGO-01 Abstracts Accepted for AACR 2026 with Significant DTH Results
Greenwich LifeSciences will present two FLAMINGO-01 abstracts at the 2026 AACR Annual Meeting, including CT138 featuring statistically significant DTH immune responses from the ongoing Phase III trial. Poster CT138 is April 20 and CT227 on April 21 detailing trial design and immunogenicity measurements using GP2 and GM-CSF.
1. Meeting Presentation
Greenwich LifeSciences will present two abstracts from its FLAMINGO-01 Phase III trial at the AACR Annual Meeting 2026, with posters scheduled on April 20 (CT138) and April 21 (CT227).
2. CT138 Immune Response Data
Abstract CT138 reports preliminary delayed-type-hypersensitivity (DTH) skin test results showing statistically significant immune activation against GP2 in breast cancer patients with residual disease or high-risk PCR after anti-HER2 therapy.
3. CT227 Trial Design Update
Abstract CT227 outlines the study design and safety assessments of GLSI-100 (GP2 + GM-CSF) in high-risk breast cancer patients, providing investigators with detailed protocol updates and trial endpoints.
4. Steering Committee Experts
The CT138 steering committee includes oncology leaders from Baylor College of Medicine, Institut Curie, Northwestern University, University Medical Center Mainz, GEICAM, Sarah Cannon Research Institute, City of Hope, Johns Hopkins, Massachusetts General Hospital and Baylor College of Medicine.